Original article
Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo

https://doi.org/10.1016/0165-4608(94)90183-XGet rights and content

Abstract

In human malignant mesothelioma cell lines an elevation of the expression of the genes for the PDGF A-chain, PDGF B-chain, and PDGF β-receptor was found compared to normal mesothelial cells. As ovarian epithelial tumors originate from the ovarian surface epithelium, which is of mesothelial origin, we investigated PDGF chain and PDGF receptor mRNA expression in six human ovarian cell lines of epithelial origin and a granulosa tumor cell line. All six investigated ovarian epithelial tumor cell lines expressed the PDGF A- and B-chain genes, while the granulosa tumor cell line expressed the PDGF A-chain gene only. Expression of PDGF receptors was not found in the epithelial or granulosa tumor cell lines. Cytogenetic and molecular biological studies did not provide evidence for rearrangement or genomic amplification of the PDGF B-chain. Expression of PDGF was also demonstrated in ovarian tumors in vivo. Frozen sections of six serous ovarian carcinomas stained positive with an antibody against PDGF and negative with antibodies against the PDGF α- and β-receptors. These results suggest that PDGF expression might be a useful marker for ovarian carcinomas.

References (22)

  • TH Parmley et al.

    The ovarian mesothelioma

    Am J Obstet Gynecol

    (1974)
  • LM Roth et al.

    General aspects of the ovarian cancer

  • RE Scully

    Tumors of the ovary and maldeveloped gonads

  • B Sorbe et al.

    Importance of histological grading in the prognosis of epithelial ovarian carcinoma

    Obstet Gynecol

    (1982)
  • JD Woodruff

    The pathogenesis of ovarian neoplasia

    John Hopkins Med J

    (1979)
  • N Auersperg et al.

    Human ovarian surface epithelium in primary culture

    In Vitro

    (1984)
  • L Papadaki et al.

    The fine structure of the surface epithelium of the human ovary

    J Cell Sci

    (1971)
  • BI Gerwin et al.

    Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines

    Cancer Res

    (1987)
  • MA Versnel et al.

    Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors

    Oncogene

    (1988)
  • MA Versnel et al.

    Human malignant mesothelioma cell lines express PDGF β-receptors whereas cultured normal mesothelial cells express predominantly PDGF α-receptors

    Oncogene

    (1991)
  • AM Van den Berg-Bakker et al.

    Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features, immunophenotype and cytogenetics

    Int J Cancer

    (1993)
  • Cited by (39)

    • Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice

      2009, Molecular Therapy
      Citation Excerpt :

      The present model showed that even the combination of antiangiogenic and antilymphangiogenic therapy was insufficient to induce tumor reggression, even though tumor vasculature was reduced throughout the tumor after the gene delivery. It is plausible that the ability of the tumors to escape the treatment is because of the upregulation of other angiogenic factors such as PDGF-B (platelet-derived growth factor),24 Ang-1 or Ang-2 (ref. 25). Although antiangiogenic agents alone are unlikely to eradicate tumors completely, similar strategies have been applied in ovarian cancer clinical trials using antihuman VEGF monoclonal antibody bevacizumab,26 soluble hybrid decoy receptor VEGF-Trap,27 tyrosine kinase inhibitor AZD 2171 (ref. 28), recombinant human IL-12 (ref. 29) and thalidomide.30

    • Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors

      2008, Gynecologic Oncology
      Citation Excerpt :

      These findings led us to explore the expression of tyrosine kinase genes where products are known to respond to imatinib and to characterize the response of the COV434 and KGN cell lines to imatinib. Several studies have examined the expression of the tyrosine kinase receptors c-kit, PDGFR-α, PDGFR-β and c-Abl in ovarian cancers [19–21] but expression profiles in GCT have not been previously reported. All four genes c-Abl, c-kit, PDGFR-α, and PDGFR-β were found to be expressed in the GCT and in the normal ovary samples.

    • Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers

      2006, Gynecologic Oncology
      Citation Excerpt :

      Imatinib has had a dramatic impact on the clinical management of select malignancies and is approved for the first-line treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia at all stages and patients with c-Kit-expressing metastatic or unresectable malignant gastrointestinal stromal tumors [2,4]. Preclinical studies of ovarian cancer indicate that c-Kit and PDGFR may have a role in ovarian tumorigenesis [5–14]. In one study, Northern blot analysis revealed c-Kit mRNA expression in two of four ovarian carcinoma samples [14].

    View all citing articles on Scopus
    View full text